• In the past week, Indivior Pharmaceuticals, Inc. reported Q1 2026 results showing sales of US$317 million and net income of US$89 million, with basic earnings per share from continuing operations rising to US$0.71 from US$0.38 a year earlier.
• Alongside this performance, the company raised its 2026 net revenue guidance to a range of US$1.22 billion to US$1.29 billion, underscoring how momentum in SUBLOCADE and tighter cost control are reshaping expectations for earnings power and capital deployment.
• We’ll now examine how Indivior’s stronger-than-expected SUBLOCADE-driven earnings and raised full-year revenue guidance might reshape the company’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Indivior Pharmaceuticals Investment Narrative Recap

To own Indivior today, you largely have to believe SUBLOCADE can keep expanding within opioid use disorder while management converts that growth into higher, cleaner earnings. The latest Q1 beat and raised 2026 revenue guidance strengthen the short term catalyst around SUBLOCADE momentum and margin improvement, but they do not remove the key risk that the long acting injectable category could stall at relatively low penetration, leaving earnings more exposed to any setback in this single product.

The most relevant recent announcement is the upgraded 2026 net revenue outlook to US$1,215 million to US$1,285 million, which directly ties into the SUBLOCADE driven growth story. That guidance, alongside strong Q1 figures and cost discipline, supports the view that Indivior’s Phase II “Accelerate” agenda can translate category adoption and pricing mix into higher adjusted EBITDA, while also highlighting how dependent the near term thesis remains on sustained SUBLOCADE uptake.

Yet against the strong quarter, investors should still be aware that if long acting injectable adoption in opioid use disorder stalls well below other chronic categories such as HIV and schizophrenia, then...

Indivior Pharmaceuticals’ narrative projects $1.2 billion revenue and $477.5 million earnings by 2028. This implies 1.7% yearly revenue growth and a $353.5 million earnings increase from $124.0 million today.

Uncover how Indivior Pharmaceuticals' forecasts yield a $37.86 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue of about US$1.3 billion and earnings near US$596 million by 2029, so after this Q1 surprise and guidance hike, it is worth asking whether that bullish view on deeper SUBLOCADE penetration and margin expansion still looks stretched or could become more realistic as new information comes through.

Explore 4 other fair value estimates on Indivior Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Indivior Pharmaceuticals research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Indivior Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Indivior Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Find 49 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.